News

Adverse, critical and unanticipated events happen every day in healthcare. The results are increased morbidity and mortality, increased length of stay and unreimbursed cost of care. Simple and intuitive visualization provides an early warning of clinical deterioration so that clinicians…

To support your surveillance and control efforts, our team has created a custom package of COVID-19 alerts. These alerts are meant to assist in identification of potential persons of interest and track the order of or positive result of a…

While the risk of the novel coronavirus (COVID-19) remains low for the general public in the United States, as indicated by both the CDC and WHO, the outbreak poses a great threat to the U.S. healthcare supply chain. This risk…

For the first time in 50 years, the Centers for Disease Control and Prevention mandates quarantine for travelers from China due to an outbreak of respiratory illness caused by a novel (new) coronavirus - COVID-19 - first identified in Wuhan,…

CHARLOTTE, N.C. -– A recent Premier Inc. (NASDAQ: PINC) analysis found that total care for patients who experienced an opioid overdose resulted in $1.94 billion in annual hospital costs across 647 healthcare facilities nationwide. Premier®, a healthcare improvement company, found that…

Florida-based health system to employ PremierConnect® pharmacy clinical surveillance and analytics across 40 hospitals to enhance medication management, antibiotic stewardship CHARLOTTE, N.C. (March 9, 2017) — Adventist Health System, a faith-based healthcare organization headquartered in Altamonte Springs, Florida, has expanded…

Today, an urgently needed tool was introduced to help US hospitals implement strategies to promote the appropriate, safe use of antibiotics. The National Quality Forum (NQF) and the Centers for Disease Control and Prevention (CDC), alongside a team of more…

Premier, Inc. (NASDAQ: PINC) has reached a definitive agreement to acquire TheraDoc, a market leading provider of clinical surveillance software, for $117 million in cash, subject to potential purchase price adjustments regarding TheraDoc’s actual working capital, cash and indebtedness at closing. The transaction is expected to close in Premier’s fiscal 2015 first quarter ending September 30, 2014, subject to customary closing conditions. TheraDoc is a wholly-owned subsidiary of Hospira (NYSE: HSP). Premier's board of directors unanimously approved the transaction, and applicable antitrust approvals have already been obtained. Based on the trailing twelve months operating earnings provided by TheraDoc, the $117 million represents a purchase price multiple in the 10-11 times range.

LAKE FOREST, Ill., Jan. 23, 2013 – Hospira (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that its TheraDoc™ Infection Control Assistant™ has been ranked as the top product in the Infection Control &…